Clinical trial
An International Multi-centre Randomised Phase II Study to Assess the Efficacy of TAK228 in Combination With Intravenous Weekly Paclitaxel Compared With Weekly Paclitaxel Alone in Women With Advanced/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)
NCT03648489 is registered in ClinicalTrials.gov with Imperial College London as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An International Multi-centre Randomised Phase II Study to Assess the Efficacy of TAK228 in Combination With Intravenous Weekly Paclitaxel Compared With Weekly Paclitaxel Alone in Women With Advanced/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)
- Lead sponsor
- Imperial College London
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 21, 2018
- Completion date
- November 30, 2023
- Enrollment
- 134 (actual)
- Sites
- 15
Conditions
As the registry lists them; a condition with its own page is linked.
fallopian tube cancer, fallopian tube neoplasms, ovarian cancer, ovarian carcinosarcoma, ovarian clear cell adenocarcinoma, ovarian endometrioid adenocarcinoma, ovarian neoplasms, ovarian serous adenocarcinoma, primary peritoneal carcinoma, primary peritoneal serous adenocarcinoma